About TD2
TD2 is a Healthcare company based in Phoenix (United States) founded in 2003, and was acquired by RCT in June 2020. Oncology preclinical and clinical development services are provided. The company has 119 employees. TD2 offers products and services including Clinical Trial Services, Preclinical Services, Regulatory Support, and Flow Cytometry Services. Its focus areas include Biopharma Outsourcing, CRO, Preclinical Studies and Oncology. Its legal entity is TRANSLATIONAL DRUG DEVELOPMENT, LLC. Its competitors include Avidity Biosciences, Vividion Therapeutics and Korro Bio; 3 of its 3 listed competitors have raised funding.
Company details
Translational Drug Development (TD2), a wholly owned subsidiary of the Translational Genomics Research Institute (TGen) is an oncology drug development organization that provides services for oncology-focused biopharmaceutical companies. It provides pre-clinical services like in vitro myeloma screening tools, in vivo imaging capabilities, image-guided micro-irradiation labs, and specialized tumor models. Besides, it offers bioanalysis and DMPK facilities. Additionally, it also offers regulatory and clinical services like FDA regulations, pre-Investigational New Drug (IND) application and IND strategies, IND submissions, FDA-regulated trials, Good Laboratory Practices (GLP); ToxicologyPharmacology Support Services.
- Headquarters Phoenix, United States
- Employees 119
- Stage Acquired
- SectorsHealthcare
- Website td2inc.com
- Social LinkedIn X
- Acquired by RCT (Jun 2020)
- Legal Name Translational Drug Development, Llc
- Investors
- Employee Count119
- Acquired byRCT
(Jun 2020)
Products & Services of TD2
TD2 offers a comprehensive portfolio of products and services, including Clinical Trial Services, Preclinical Services, Regulatory Support, and Flow Cytometry Services.
Design and execution of oncology clinical trials
Development of cancer models and bioanalytical services
Assistance with IND filings and FDA interactions
Analysis of drug effects on immune cells
Investors in TD2
TD2 has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include Research Corporation Technologies.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Research Corporation Technologies is engaged in licensing biomedical technologies. | rctech.com | Tucson, United States |
Investor details for TD2
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of TD2
30 people are tracked at TD2 (12 in leadership, 18 in team); the tracked headcount is 119.
| Name | Role | Group |
|---|---|---|
Tom Arnold | Senior Director, Business Development | Leadership |
Jennifer Vergara | Senior Director, Clinical Data Services | Leadership |
Stephen Gately | CEO | Leadership |
Alan Miller M.D. | Chief Medical Officer | Leadership |
Shawnna Rustenbeck | Vice President Of Finance And Operations | Leadership |
Marc Appelbaum | Vice President Of Sales | Leadership |
Maggie Valenzuela Murray | Director, Nonclinical Operations | Leadership |
Erin Trachet | Senior Director Scientific Engagement | Leadership |
Andrew H. | Director Of Business Operations | Leadership |
Damaris Diaz | Associate Director - Laboratory Operations | Leadership |
Susan Night | Sr. Vice President, Strategy And Growth | Leadership |
Susan Tessmann | Vice President, Clinical | Leadership |
Rachel Dukes | Clinical Data Associate II | Team |
Caroline Nehme | Clinical Data Manager | Team |
Adeline Chin | Clinical Data Associate | Team |
Ryan Ellsworth | Senior Clinical Programmer | Team |
Stephanie N. | Data Specialist II | Team |
Kacey Champion | Accounting Manager And System Administrator | Team |
Dawn Moris | Senior Clinical Data Manager | Team |
Ccdm Micheal Maduka | Lead Clinincal Data Manager | Team |
10 more people are available in the full profile.
Complete people profiles for TD2
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of TD2
2 dated milestones of TD2 across 17 years, from founding to its latest funding, stage changes and deals.
- Founded TD2 is founded.
- Exit Acquired by RCT.
Competitors of TD2
TD2 has 3 listed competitors in our database, 3 of them funded. They include Avidity Biosciences, Vividion Therapeutics and Korro Bio.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| aviditybiosciences.com | 2012 | San Diego, United States | $142.54M | 253 | Antibody-siRNA complexes are developed for cancer treatment. | |
| vividion.com | 2016 | Oceanside, United States | $270.5M | 123 | Developing novel drugs based on a proteome-wide ligand and target discovery platform | |
| korrobio.com | 2018 | Cambridge, United States | $4M | 77 | RNA-editing technologies are provided for precision medicine applications. |
Detailed competitors of TD2
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of TD2
The website of TD2 (td2inc.com) receives about 4.1K visits a month.
- Monthly visits4.1K
▼ 14.1% vs previous month
Top companies in Life Sciences Platforms & Tools
3 companies that operate in the same segment as TD2 (Life Sciences Platforms & Tools) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Medidata is recognized as a leading provider of SaaS solutions for clinical research. | 1999 | New York, New York, United States | USD 41.5 M | |||
AI-based solutions for health management are provided. | 2015 | Dallas, Texas, United States | USD 2.8 B | 1,111 | ||
Real-world health data is provided for research and decisions. | 2012 | Menlo Park, California, United States | USD 259.16 M |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Td2
Complete news archive for TD2
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about TD2
TD2 was founded in 2003.
TD2 is headquartered in Phoenix, United States. It is registered at Phoenix, Arizona, United States.
TD2 has 119 employees.
Translational Drug Development (TD2), a wholly owned subsidiary of the Translational Genomics Research Institute (TGen) is an oncology drug development organization that provides services for oncology-focused biopharmaceutical companies. It provides pre-clinical services like in vitro myeloma screening tools, in vivo imaging capabilities, image-guided micro-irradiation labs, and specialized tumor models. Besides, it offers bioanalysis and DMPK facilities. Additionally, it also offers regulatory and clinical services like FDA regulations, pre-Investigational New Drug (IND) application and IND strategies, IND submissions, FDA-regulated trials, Good Laboratory Practices (GLP); ToxicologyPharmacology Support Services.
TD2's top competitors include Avidity Biosciences, Vividion Therapeutics and Korro Bio.
TD2 offers Clinical Trial Services, Preclinical Services, Regulatory Support, and Flow Cytometry Services.
TD2 has 1 investor. Key investors include Research Corporation Technologies.
TD2 operates through Translational Drug Development, Llc.
Yes. TD2 was acquired by RCT in June 2020.